23ME-00610, a genetically informed, first-in-class antibody targeting CD200R1 to enhance antitumor T cell function

Immune checkpoint inhibition (ICI) has revolutionized cancer treatment; however, only a subset of patients benefit long term. Therefore, methods for identification of novel checkpoint targets and development of therapeutic interventions against them remain a critical challenge. Analysis of human gen...

Descripción completa

Detalles Bibliográficos
Autores principales: Fenaux, Jill, Fang, Xin, Huang, Yao-ming, Melero, Cristina, Bonnans, Caroline, Lowe, Earth Light, Palumbo, Tiziana, Lay, Cecilia, Yi, Zuoan, Zhou, Aileen, Poggio, Mauro, Chung, Wei-Jen, Majeed, Sophia R., Glatt, Dylan, Chen, Alice, Schmidt, Maike, Lee, Clarissa C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10243377/
https://www.ncbi.nlm.nih.gov/pubmed/37288324
http://dx.doi.org/10.1080/2162402X.2023.2217737

Ejemplares similares

Ejemplares similares